Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Piper Jaffray Companies raised their Q1 2019 EPS estimates for shares of Exelixis in a note issued to investors on Tuesday, February 12th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the biotechnology company will post earnings of $0.27 per share for the quarter, up from their previous estimate of $0.25. Piper Jaffray Companies currently has a “Overweight” rating and a $26.00 target price on the stock. Piper Jaffray Companies also issued estimates for Exelixis’ Q1 2020 earnings at $0.37 EPS, Q2 2020 earnings at $0.37 EPS, Q3 2020 earnings at $0.38 EPS, Q4 2020 earnings at $0.38 EPS and FY2020 earnings at $1.50 EPS.
Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.14. The company had revenue of $228.60 million during the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The firm’s revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share.
Several other analysts also recently commented on EXEL. Zacks Investment Research downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Monday. Oppenheimer lowered their target price on shares of Exelixis from $40.00 to $31.00 and set an “outperform” rating for the company in a report on Wednesday. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a report on Monday, December 17th. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Saturday, January 19th. Finally, ValuEngine upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $27.25.
Shares of EXEL stock opened at $22.05 on Thursday. The stock has a market capitalization of $6.59 billion, a PE ratio of 43.24, a PEG ratio of 1.34 and a beta of 2.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.54. Exelixis has a one year low of $13.42 and a one year high of $30.24.
In related news, Director George A. Scangos sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $21.16, for a total transaction of $846,400.00. Following the completion of the sale, the director now owns 1,505,481 shares in the company, valued at $31,855,977.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick J. Haley sold 9,120 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The stock was sold at an average price of $22.18, for a total transaction of $202,281.60. The disclosure for this sale can be found here. Insiders have sold 337,807 shares of company stock valued at $7,248,232 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the business. FTB Advisors Inc. boosted its position in Exelixis by 312.0% during the fourth quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,170 shares during the period. JOYN Advisors Inc. boosted its position in Exelixis by 334.2% during the fourth quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 1,173 shares during the period. Cornerstone Advisors Inc. bought a new position in Exelixis during the fourth quarter worth about $38,000. Financial Gravity Companies Inc. bought a new position in Exelixis during the fourth quarter worth about $50,000. Finally, Laurel Wealth Advisors LLC bought a new position in Exelixis during the fourth quarter worth about $59,000. Hedge funds and other institutional investors own 78.28% of the company’s stock.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Recommended Story: Liquidity
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.